Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana

Launched by UNIVERSITY HOSPITAL CENTER OF MARTINIQUE · Mar 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how envenomation from different species of Bothrops snakes affects a substance in the blood called Willebrand factor, which plays an important role in blood clotting. The researchers want to understand how the activity of Willebrand factor changes depending on the species of snake that bites a person, particularly in Martinique and French Guiana. By analyzing this, they hope to find out why some snake bites lead to serious bleeding while others cause blood clots or other complications. The ultimate goal is to improve treatment for patients who suffer from snakebites.

To participate in this study, individuals must be at least 18 years old and have been bitten by a confirmed Bothrops snake, experiencing severe symptoms of envenomation. Participants will be admitted to the emergency department and will need to give their consent to take part in the research. Throughout the trial, they can expect to undergo various tests to measure Willebrand factor activity and its effects on their health. It’s important for potential participants to know that this study aims to enhance understanding of snakebite effects, which could lead to more personalized and effective treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or Women, at least 18 years old
• • Be admitted to the Emergency Department of the Martinique University Hospital or the Cayenne University Hospital
• • Be the victim of a confirmed Bothrops snake bite in Martinique or French Guyana. The formal identification of the snake by the patient or his entourage is imperative.
• • Have a confirmed diagnosis of stage III envenomation (regional oedema of the limb and/or moderate general symptoms such as moderate hypotension, malaise, vomiting, abdominal pain, diarrhoea) and stage IV (extensive oedema reaching the trunk and/or severe general symptoms such as prolonged hypotension, shock, anaphylactoid reaction, visceral damage)
• • Be able to receive and understand information related to the research
• • Be able to freely give verbal consent to participate in the proposed research
• • Be able to freely give written informed consent to participate in the plasmathèque
• • Be affiliated to the general social security system
• Exclusion Criteria:
• • Pregnant or breastfeeding woman
• • People who have been treated for snakebite with Bothrops anti-venom Bothrofav® or Antivipmyn-tri®.
• • Known disorders of haemostasis such as haemophilia A (factor VIII deficiency), haemophilia B (factor IX deficiency), vitamin K deficiency, hepato-cellular insufficiency, presence of circulating anticoagulant factors
• • Disseminated intravascular coagulation (DIC)
• • Constitutional and acquired Von Willebrand disease
• • Constitutional and acquired thrombopathies
• • Idiopathic thrombocytopenic purpura
• • Person under legal protection (guardianship, curatorship, safeguard of justice), and person deprived of liberty.